Trial · NCT04711135
Results by group28
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 28
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Absorbed Radiation Doses in Target Organ | GEP-NET | Kidney | 0.71 | Standard Deviation 0.25 | Gy/GBq |
| Absorbed Radiation Doses in Target Organ | PPGL | Kidney | 0.82 | Standard Deviation 0.32 | Gy/GBq |
| Absorbed Radiation Doses in Target Organ | GEP-NET | Pituitary | 1.2 | Standard Deviation 0.43 | Gy/GBq |
| Absorbed Radiation Doses in Target Organ | PPGL | Pituitary | 1.0 | Standard Deviation 0.45 | Gy/GBq |
| Absorbed Radiation Doses in Target Organ | GEP-NET | Red Marrow (Blood) | 0.024 | Standard Deviation 0.0035 | Gy/GBq |
| Absorbed Radiation Doses in Target Organ | PPGL | Red Marrow (Blood) | 0.028 | Standard Deviation 0.0052 | Gy/GBq |
| Absorbed Radiation Doses in Target Organ | GEP-NET | Red Marrow (Image) | 0.043 | Standard Deviation 0.018 | Gy/GBq |
| Absorbed Radiation Doses in Target Organ | PPGL | Red Marrow (Image) | 0.067 | Standard Deviation 0.028 | Gy/GBq |
| Absorbed Radiation Doses in Target Organ | GEP-NET | Spleen | 0.63 | Standard Deviation 0.39 | Gy/GBq |
| Absorbed Radiation Doses in Target Organ | PPGL | Spleen | 0.82 | Standard Deviation 0.17 | Gy/GBq |
| Absorbed Radiation Doses in Target Organ | GEP-NET | Urinary Bladder Wall | 0.50 | Standard Deviation 0.034 | Gy/GBq |
| Absorbed Radiation Doses in Target Organ | PPGL | Urinary Bladder Wall | 0.59 | Standard Deviation 0.096 | Gy/GBq |
| Absorbed Radiation Doses in Target Organ | GEP-NET | Total Body | 0.040 | Standard Deviation 0.013 | Gy/GBq |
| Absorbed Radiation Doses in Target Organ | PPGL | Total Body | 0.041 | Standard Deviation 0.0073 | Gy/GBq |
| Incidence of Adverse Events (AEs) and Lab Toxicities After 1st Lutathera Administration | GEP-NET | 4 | Participants | ||
| Incidence of Adverse Events (AEs) and Lab Toxicities After 1st Lutathera Administration | PPGL | 6 | Participants | ||
| Incidence of Adverse Events (AEs) During Treatment and Short-term Follow-up | GEP-NET | AEs during Lutathera treatment | 4 | Participants | |
| Incidence of Adverse Events (AEs) During Treatment and Short-term Follow-up | PPGL | AEs during Lutathera treatment | 7 | Participants | |
| Incidence of Adverse Events (AEs) During Treatment and Short-term Follow-up | GEP-NET | AEs during short-term follow-up | 1 | Participants | |
| Incidence of Adverse Events (AEs) During Treatment and Short-term Follow-up | PPGL | AEs during short-term follow-up | 3 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04711135/results